Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 11Thoracic 5Dermatologic 4Genitourinary 2Gastrointestinal 2

Conditions

Colorectal Neoplasms 29Carcinoma, Non-Small-Cell Lung 17Pancreatic Neoplasms 12Neoplasm Metastasis 9Stomach Neoplasms 7Lung Neoplasms 7Rectal Neoplasms 6Neoplasms 6Melanoma 6Esophageal Neoplasms 6Colonic Neoplasms 6Ovarian Neoplasms 4Gastrointestinal Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Liver Neoplasms 2Hypopharyngeal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Biliary Tract Neoplasms 2Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Diseases 1

Interventions

pembrolizumab 49Nivolumab 21Cisplatin 11Cetuximab 11Carboplatin 10Paclitaxel 8Gemcitabine 8Docetaxel 8atezolizumab 7Ipilimumab 7Cyclophosphamide 7spartalizumab 6durvalumab 6Fluorouracil 6Capecitabine 6fludarabine 5avelumab 5Albumin-Bound Paclitaxel 5cemiplimab 4Trastuzumab 4Taxes 4Oxaliplatin 4Leucovorin 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3tisotumab vedotin 3aldesleukin 3Specimen Handling 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Pemetrexed × Gastrointestinal × Clear all
NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
350 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡